# OnCo record howard-kaufman (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/howard-kaufman/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "howard-kaufman" ;
  schema:name "Howard L. Kaufman"@en ;
  schema:description "Led OPTiM, the trial that made talimogene laherparepvec the first approved oncolytic virus therapy."@en ;
  schema:url <https://onco.cc/people/howard-kaufman/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Kaufman%20HL%5BAuthor%5D%20talimogene%20oncolytic> ;
  onco:tag "immunotherapy", "oncolytic-virus", "melanoma" ;
  schema:jobTitle "Surgical Oncologist, Massachusetts General Hospital; Chief Medical Officer, Ankyra Therapeutics" ;
  schema:sameAs <https://orcid.org/0000-0003-1131-004X> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/merkel-cell-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> ;
  onco:drugs <https://onco.cc/drugs/talimogene-laherparepvec/> ;
  onco:institutions <https://onco.cc/institutions/mgh/>, <https://onco.cc/institutions/sitc/> ;
  onco:journals <https://onco.cc/journals/nature-reviews-drug-discovery/> ;
  schema:affiliation <https://onco.cc/institutions/mgh/> .